Status:
UNKNOWN
The Recurrence Study
Lead Sponsor:
Hamad Medical Corporation
Conditions:
Acute Stroke
Transient Ischemic Attack
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The primarily goal of the research is to better understand progression of disease in patients who present with an acute stroke to the Hamad General Hospital (HGH) stroke and Transient Ischemic Attack ...
Detailed Description
Patient admitted to the stroke service with acute stroke and TIAs will be eligible for the study. The study will enroll patients at Hamad General Hospital in the setting of the Stroke Ward. The inves...
Eligibility Criteria
Inclusion
- Subjects 18 years and older
- Subjects willing to give consent and agree to regular follow up visits;
- Male/Female patients of all nationalities admitted to HGH or seen in the Stroke Ward/ TIA clinics with a confirmed diagnosis of acute stroke and TIA, confirmed on the initial standard of care ordered MRI imaging.
- Stroke onset is less than 48 hours.
Exclusion
- Pregnant women or individuals with cognitive disabilities.
- individuals with onset \> 48 hours.
Key Trial Info
Start Date :
February 17 2016
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
May 17 2018
Estimated Enrollment :
300 Patients enrolled
Trial Details
Trial ID
NCT03244215
Start Date
February 17 2016
End Date
May 17 2018
Last Update
August 9 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The Neuroscience Institute, Hamad Medical Corporation
Doha, Qatar, 3500